Oculis Holding AG(OCS)Earnings, Financials & Key RatiosOculis Holding AG (OCS) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's lack of commercial revenue and persistent quarterly cash burn of $15.5 million in 2026Q1 create a binary risk profile that outweighs current liquidity buffers.
Oculis Holding AG (OCS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Oculis Holding AG (OCS) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.63vs $0.49-28.6% | $253,185vs $253,794-0.2% |
| Q2 2026 | Mar 3, 2026 | $0.51vs $0.48-6.7% | $518,435vs $142,917+262.8% |
| Q4 2025 | Nov 10, 2025 | $0.40vs $0.50+20.0% | $305,460vs $136,870+123.2% |
| Q3 2025 | Aug 21, 2025 | $0.59vs $0.53-11.3% | $328,476vs $143,340+129.2% |
Recent stock market news and headlines for Oculis Holding AG (OCS)
ZUG, Switzerland, July 2, 2026 – Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant unmet medical needs, announced today that Oculis' management will participate in a fireside chat at the Piper Sandler Virtual Ophthalmology Conference.
Key metrics vs top competitors for Oculis Holding AG (OCS)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $13.56 | $775.22M | -6.04 | -100% | — | -70.09% | — | |
| $4.07 | $444.42M | -2.02 | — | — | -70.79% | — | |
| $1.51 | $33.11M | -0.46 | — | — | -1335.64% | — | |
| $5.90 | $184.99M | -2.07 | — | -519.3% | -46.82% | — | |
| $123.77 | $9.1B | -21.16 | — | — | -42.78% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
Oculis Holding AG (OCS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when OCS posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Oculis Holding AG (OCS) stock FAQ — growth, dividends, profitability & financials explained
Oculis Holding AG (OCS) reported $0.5M in revenue for fiscal year 2025.
Oculis Holding AG (OCS) saw revenue decline by 100.0% over the past year.
Oculis Holding AG (OCS) reported a net loss of $95.1M for fiscal year 2025.
Oculis Holding AG (OCS) has a return on equity (ROE) of -70.1%. Negative ROE indicates the company is unprofitable.
Oculis Holding AG (OCS) had negative free cash flow of $62.5M in fiscal year 2025, likely due to heavy capital investments.
